Previous 10 | Next 10 |
With the biggest ever intra-day loss, Reata Pharmaceuticals (RETA -46.1%) is trading at the lowest level since May 2018 after the efforts to introduce its first-ever commercialized product suffered a setback following a negative vote from an FDA expert panel. With the support of data fro...
Gainers: Inspira Technologies (NASDAQ:IINN) +92%. Ensysce Biosciences (NASDAQ:ENSC) +79%. Insignia (NASDAQ:ISIG) +44%. Hovnanian Enterprises (NASDAQ:HOVNP) +33%. American Virtual Cloud Technologies (NASDAQ:AVCT) +31%. Blue Star Foods Corp. (NASDAQ:BSFC) +16%. Hovnanian (NYSE:HO...
Shares of Reata Pharmaceuticals (NASDAQ: RETA) got hammered in early trading Thursday, plunging as much as 43%. As of 11:18 a.m. ET, the stock was still down 42.7%. The catalyst that sent the clinical-stage biopharmaceutical company reeling was an adverse opinion by a Food a...
Gainers: Inspira Technologies (NASDAQ:IINN) +103%, Ensysce Biosciences (NASDAQ:ENSC) +53%, Jasper Therapeutics (NASDAQ:JSPR) +24%, Ambrx Biopharma (NYSE:AMAM) +17%, iSpecimen (NASDAQ:ISPC) +15%. Losers: Reata Pharmaceuticals (NASDAQ:RETA)...
After three days of strong gains, Wall Street looks ready to take a bit of a break. Thursday morning brought modest pullbacks in most major stock indexes, as market participants turn their attention to economic data over the next couple of days to guide their longer-term strategies. As of 8...
Reata Pharmaceuticals (NASDAQ:RETA) -41% after announcing outcome of AdCom vote. Code Chain New Continent (NASDAQ:CCNC) -31% Torrid Holdings (NYSE:CURV) -24% on Q3 earnings release. Triterras (NASDAQ:TRIT) -18% provides further update on independent audit of fin...
Reata Pharmaceuticals (NASDAQ:RETA) has lost ~42.8% in the pre-market after the company announced that an expert panel of the FDA voted “no” to a key question on the approval of its experimental oral drug bardoxolone methyl for chronic kidney disease (“CKDȁ...
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Reata Pharmaceuticals, Inc. (“Reata” or the “Company”) (NASDAQ: RETA) on behalf of Reata stockholders. Our investigation concerns w...
Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), today announced the outcome of the U.S. Food and Drug Administration (“FDA”) Cardiovascular and Renal Drugs Advisory Committee (“Committee”...
The Nasdaq has halted trading of Reata Pharmaceuticals' (NASDAQ:RETA) common stock. The FDA's Cardiovascular and Renal Drugs Advisory Committee is meeting to review the Company’s New Drug Application (NDA) for bardoxolone methyl for the treatment of patients with chronic kidney di...
News, Short Squeeze, Breakout and More Instantly...
Reata Pharmaceuticals Inc. Company Name:
RETA Stock Symbol:
NASDAQ Market:
Reata Pharmaceuticals Inc. Website:
Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...
Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023
Reata acquisition bolsters Biogen’s rare disease portfolio with the addition of SKYCLARYS ® (omaveloxolone), the first and only FDA approved treatment for Friedreich’s ataxia in the U.S. CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (N...